# US 5,702,909 A · Methods of detecting collagen type II degradation in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,702,909 A
- Document ID: US5702909A
- Status: Granted
- Kind: A
- Application number: 08/484,833
- Filed: 1995-06-07
- Granted: 1997-12-30
- Earliest claimed: 1987-11-06
- Assignees: Washington Research Foundation
- Inventors: David R. Eyre
- Web page: https://patentgrep.com/patent/US5702909A

## CPC

- C07K 16/18: against material from animals or humans
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/4712: Muscle proteins, e.g. myosin, actin, protein
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- G01N 2800/105: Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- G01N 2800/108: Osteoporosis
- Y10S 435/975: Kit
- Y10S 436/808: Automated or kit
- Y10S 436/811: Test for named disease, body condition or organ function
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

In a method of analyzing a body fluid sample for the presence of an analyte indicative of a physiological condition, comprising the steps of contacting the body fluid sample with an immunological binding partner which binds to the analyte, detecting binding of the immunological binding partner to the analyte, and correlating any detected binding to the physiological condition, the improvement comprising contacting the body fluid sample with an immunological binding partner which binds to ##STR1## wherein ##STR2## is hydroxylysyl pyridinoline or lysyl pyridinoline, and correlating any detected binding to degradation of type II collagen in vivo.

## Claims

### Claim 1

In a method of analyzing a body fluid sample for the presence of an analyte indicative of a physiological condition, comprising the steps of contacting the body fluid sample with an immunological binding partner which binds to the analyte, detecting binding of the immunological binding partner to the analyte, and correlating any detected binding to the physiological condition, the improvement comprising contacting the body fluid sample with an immunological binding partner which binds to ##STR28## wherein ##STR29## is hydroxylysyl pyridinoline or lysyl pyridinoline, and correlating any detected binding to degradation of type II collagen in vivo.

### Claim 2

A kit for assaying in vivo degradation of type II collagen, comprising an immunological binding partner which binds to ##STR30## wherein ##STR31## is hydroxylysyl pyridinoline or lysyl pyridinoline.

### Claim 3

A cell line that produces an immunological binding partner which binds to ##STR32## wherein ##STR33## is hydroxylysyl pyridinoline or lysyl pyridinoline.

### Claim 4

An immunological binding partner which binds to ##STR34## wherein ##STR35## is hydroxylysyl pyridinoline or lysyl pyridinoline.

### Claim 5

An immunological binding partner which binds to ##STR36## wherein ##STR37## is hydroxylysyl pyridinoline or lysyl pyridinoline, wherein said immunological binding partner does not cross-react more than 10% with ##STR38## wherein Hyl-Hyl-Hyl is hydroxylysyl pyridinoline.